Triiodothyronine (T3) does not induce Rankl expression in rat Ros 17/2.8 cells

Arq Bras Endocrinol Metabol. 2008 Feb;52(1):109-13. doi: 10.1590/s0004-27302008000100015.

Abstract

Osteoclastogenesis may be regulated via activation of the RANK/RANKL (receptor activator of nuclear factor-kappa B/receptor activator of nuclear factor-kappa B ligand) system, which is mediated by osteoblasts. However, the bone loss mechanism induced by T3 (triiodothyronine) is still controversial. In this study, osteoblastic lineage rat cells (ROS 17/2.8) were treated with T3 (10(-8) M, 10(-9) M, and 10(-10) M), and RANKL mRNA (messenger RNA) expression was measured by semiquantitative RT-PCR. Our results show that T3 concentrations used did not significantly enhance RANKL expression compared to controls without hormone treatment. This data suggests that other mechanisms, unrelated to the RANK/RANKL system, might be to activate osteoclast differentiation in these cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Resorption / drug therapy*
  • Bone Resorption / metabolism
  • Cell Differentiation / drug effects
  • Electrophoresis, Agar Gel
  • Osteoblasts / cytology
  • Osteoblasts / drug effects*
  • Osteoclasts / metabolism
  • RANK Ligand / genetics
  • RANK Ligand / metabolism*
  • RNA, Messenger / metabolism*
  • Rats
  • Receptors, Thyroid Hormone / genetics
  • Receptors, Thyroid Hormone / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Triiodothyronine / pharmacology*

Substances

  • RANK Ligand
  • RNA, Messenger
  • Receptors, Thyroid Hormone
  • Triiodothyronine